GW Pharmaceuticals plc: 06/05/2015 GW Pharmaceuticals to Report Q2 2015 Financial Results and Host Conference Call on 11 May, 2015

Tickers: GWPH
May 6, 2015

GW Pharmaceuticals to Report Q2 2015 Financial Results and Host Conference Call on 11

May, 2015

LONDON, UK, 6 May 2015 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 11 May, 2015 its second quarter and half year financial results for the period ending 31 March, 2015. GW will also host a conference call the same day at 8:00 a.m. EDT (1:00 p.m. BST).

Top Company Interviews

Microsoft Corporation
Intel Corporation
Pfizer, Inc.
General Electric Company
Wal-Mart Stores, Inc.
Conference call information will be provided in the financial results press release. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call.

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 27 countries outside the United States. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex®, which is in Phase 3 clinical development for the treatment of Dravet syndrome and which is also expected to enter Phase 3 clinical trials in the treatment of Lennox-Gastaut syndrome and Tuberous Sclerosis Complex. GW has a deep pipeline of additional cannabinoid product candidates which includes Sativex in Phase 3 clinical development as a potential treatment of pain associated with advanced cancer, as well as compounds in Phase 1 and 2 trials for glioma, ulcerative colitis, type 2 diabetes, and schizophrenia. For further information, please visit www.gwpharm.com.

Enquiries:

GW Pharmaceuticals plc (Today) +44 20 3727 1000

Stephen Schultz, VP Investor Relations (U.S.) 917 280 2424 / 401 500 6570

FTI Consulting (Media Enquiries)

Ben Atwell / Simon Conway / John Dineen (UK) + 44 20 3727 1000

Robert Stanislaro (U.S.) 212 850 5657

Trout Group, LLC (U.S. investor relations)

Todd James / Chad Rubin 646 378 2900

distributed by

This content was issued by GW Pharmaceuticals plc on the 2015-05-06 and was initially posted on www.gwpharm.com. It was distributed, unedited and unaltered, by noodls on 2015-05-06 11:14:17 UTC. The original issuer is solely responsible for the accuracy of the information contained therein.